RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

Consensus on best practices for addressing red flag behaviors in pain patients who seek long-acting opioids.
An experimental heroin analog may provide a new tool in the prevention of opioid addiction and improvement of withdrawal symptoms.
As the year comes to a close, Practical Pain Management
After the alleged Trump ban on evidence- and science-based terminology, clinicians weigh in on the importance of their approach in practical medicine.
FDA expanded their policy guidance on the use of stem cells and tissue products in regenerative medicine
Half of pain patients discontinued use of opioids, and another 30% were able to transition off all pain medication, according to OPERA study authors
Cone snail venom offers new therapeutic - and opioid alternative - possibilities for neutralizing chronic pain.
Consensus recommendations for the best way to employ urine drug monitoring when prescribing opioids for patients with chronic pain in primary care.
Patients who use street drugs, particularly meth are at increased risk for heart failure and should be directed to rehab programs.
Researchers presented a methodology for stimulating new tissue formation based on cyclical hydrostatic pressure, perhaps leading to cartilage regeneration as a means to restore joint health.
IV infused golimumab may improve function and disease management in patients suffering from inflammatory and joint pain.
In 2015, PPM published “Methadone for Pain Management,”1 which cited that one-third of opioid-implicated deaths were caused by methadone.
Patients who take opioids and drink coffee less pain-related symptoms and depressiion, and higher physical function than patients taking opioids who avoid caffeine.
The first, wearable, noninvasive neurostimulation device, the Bridge, reduced symptoms of opioid withdrawal to achieve 89% success in transitioning to long-term care.
New pain management formulations may impact opioid prescribing and usage: Scripps looks into the G protein and beta-arestin pathways, including fentanyls's role, Daiichi Sankyo releases MorphaBond ER, and FDA moves forward two buprenorphine products to treat opioid use disorder.
close X
SHOW MAIN MENU
SHOW SUB MENU